Original Article

You have full text access to this OnlineOpen article

The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase

  1. Franca Piras Ph.D.1,
  2. Romano Colombari M.D.2,
  3. Luigi Minerba Ph.D.3,
  4. Daniela Murtas Ph.D.1,
  5. Carlo Floris M.D.4,
  6. Cristina Maxia Ph.D.1,
  7. Arianna Corbu Ph.D.1,5,
  8. M. Teresa Perra Ph.D.1,
  9. Paola Sirigu M.D., Ph.D.1,†,*

Article first published online: 2 AUG 2005

DOI: 10.1002/cncr.21283

Issue

Cancer

Cancer

Volume 104, Issue 6, pages 1246–1254, 15 September 2005

Additional Information

How to Cite

Piras, F., Colombari, R., Minerba, L., Murtas, D., Floris, C., Maxia, C., Corbu, A., Perra, M. T. and Sirigu, P. (2005), The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer, 104: 1246–1254. doi: 10.1002/cncr.21283

Author Information

  1. 1

    Department of Cytomorphology, University of Cagliari, Cagliari, Italy

  2. 2

    Surgical Pathology, Department of Diagnostics, City Hospital, Arzignano, Vicenza, Italy

  3. 3

    Department of Public Health, ASL 8, Cagliari, Italy

  4. 4

    Oncologic Hospital “Businco,” Medical Oncology Division II, Cagliari, Italy

  5. 5

    Policlinico S. Orsola-Malpighi, Center for Applied Biomedical Research, Bologna, Italy

  1. †

    Fax: (011) 39 0706754003

*Department of Cytomorphology, University of Cagliari, Cittadella Universitaria, 09042 Monserrato (CA), Italy

Publication History

  1. Issue published online: 31 AUG 2005
  2. Article first published online: 2 AUG 2005
  3. Manuscript Accepted: 25 APR 2005
  4. Manuscript Revised: 18 APR 2005
  5. Manuscript Received: 10 NOV 2004

Funded by

  • Regione Autonoma della Sardegna
  • Assessorato dell'Igiene e Sanità e dell'Assistenza Sociale
  • Fondazione Banco di Sardegna

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (588K)

REFERENCES

  • 1
    Clark WH Jr., Elder DE, Guerry DP IV, et al. Model predicting survival in Stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81: 1893–1904.
  • 2
    Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002; 138: 603–608.
  • 3
    Ostmeier H, Fuchs B, Otto F, et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol. 2001; 145: 203–209.
    Direct Link:
  • 4
    Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS. Below thickness and Clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer staging. Cancer. 2000; 88: 589–595.
  • 5
    Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol. 2001; 137: 1169–1173.
  • 6
    Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer. 1995; 75: 478–494.
    Direct Link:
  • 7
    Ribatti D, Ennas MG, Vacca A, et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest. 2003; 33: 420–425.
    Direct Link:
  • 8
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 3635–3648.
  • 9
    Balch CM. Cutaneous melanoma. In: GreeneFL, PageDL, FlemingID, et al., editors. AJCC cancer staging manual, 6th ed. New York: Springer Verlag, 2002: 209–217.
  • 10
    Carlson JA, Slominski A, Linette GP, et al. Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. Am J Clin Pathol. 2003; 120(Suppl): 101–127.
  • 11
    Cook MG. The significance of inflammation and regression in melanoma. Virchows Arch A Pathol Anat Histopathol. 1992; 420: 113–115.
  • 12
    Busam KJ, Antonescu CR, Marghoob AA. Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. Am J Clin Pathol. 2001; 115: 856–860.
  • 13
    Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996; 77: 1303–1310.
    Direct Link:
  • 14
    Mihm MC Jr., Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996; 74: 43–47.
  • 15
    Tuthill RJ, Unger JM, Liu PY, Flaherty LE, Sondak VK. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 2002; 4: 504–511.
  • 16
    Hakansson A, Gustafsson B, Krysander L, Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer. 1996; 74: 670–676.
  • 17
    Hakansson A, Gustafsson B, Krysander L, Hakansson L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res. 1998; 18: 33–39.
  • 18
    Hakansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Hakansson L. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer. 2001; 85: 1871–1877.
  • 19
    Håkansson A, Håkansson L, Gustafsson B. On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation. Melanoma Res. 2003; 13: 401–407.
  • 20
    Qiang L, Yi J, Fu-De C. Melanoma vaccine based on the vector of membrane fusogenic liposomes. Pharmazie. 2004; 59: 263–267.
  • 21
    Obata C, Zhang M, Moroi Y, et al. Formalin-fixed tumor cells effectively induce antitumor immunity both in prophylactic and therapeutic conditions. J Dermatol Sci. 2004; 34: 209–219.
  • 22
    Dissanayake SK, Thompson JA, Bosch JJ, et al. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex Class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. 2004; 64: 1867–1874.
  • 23
    Konstadoulakis MM, Vezeridis M, Hatziyianni E, et al. Molecular oncogene markers and their significance in cutaneous malignant melanoma. Ann Surg Oncol. 1998; 5: 253–260.
  • 24
    Zehntner S, Townsend W, Parkes J, et al. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology. 1999; 31: 116–122.
  • 25
    Torisu-Itakura H, Furue M, Kuwano M, Ono M. Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas. Jpn J Cancer Res. 2000; 91: 906–910.
  • 26
    Bodey B, Bodey B Jr., Siegel SE, Kaiser HE. Controversies on the prognostic significance of tumor infiltrating leukocytes in solid human tumors. Anticancer Res. 2000; 20: 1759–1768.
  • 27
    Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology, 3rd ed. Philadelphia: WB Saunders Company, 1997.
  • 28
    Bernsen MR, Diepstra JH, van Mil P, et al. Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells. J Pathol. 2004; 202: 70–79.
    Direct Link:
  • 29
    Riley PA. Melanoma and the problem of malignancy. Tohoku J Exp Med. 2004; 204: 1–9.
  • 30
    Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001; 159: 237–243.
  • 31
    Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol. 2003; 200: 255–268.
    Direct Link:
  • 32
    Salio M, Cella M, Vermi W, et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol. 2003; 33: 1052–1062.
    Direct Link:
  • 33
    Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42: 1414–1421.
  • 34
    Ladanyi A. Function and prognostic significance of immune cells infiltrating human tumors. Magy Onkol. 2004; 48: 49–56.
View Full Article (HTML) Get PDF (588K)